Now showing items 21-28 of 28

    • Mortality and cancer incidence in carriers of constitutional t(11;22)(q23;q11) translocations: A prospective study. 

      Schoemaker, MJ; Jones, ME; Higgins, CD; Wright, AF; UK Clinical Cytogenetics Group; Swerdlow, AJ (2019-09)
      The constitutional t(11;22)(q23;q11) translocation is the only recurrent non-Robertsonian translocation known in humans. Carriers are phenotypically normal and are usually referred for cytogenetic testing because of multiple ...
    • Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers. 

      Khalique, S; Naidoo, K; Attygalle, AD; Kriplani, D; Daley, F; Lowe, A; Campbell, J; Jones, T; Hubank, M; Fenwick, K; Matthews, N; Rust, AG; Lord, CJ; Banerjee, S; Natrajan, R (2018-07-20)
      ARID1A is a tumour suppressor gene that is frequently mutated in clear cell and endometrioid carcinomas of the ovary and endometrium and is an important clinical biomarker for novel treatment approaches for patients with ...
    • Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. 

      Abubakar, M; Orr, N; Daley, F; Coulson, P; Ali, HR; Blows, F; Benitez, J; Milne, R; Brenner, H; Stegmaier, C; Mannermaa, A; Chang-Claude, J; Rudolph, A; Sinn, P; Couch, FJ; Devilee, P; Tollenaar, RAEM; Seynaeve, C; Figueroa, J; Sherman, ME; Lissowska, J; Hewitt, S; Eccles, D; Hooning, MJ; Hollestelle, A; Martens, JWM; van Deurzen, CHM; kConFab Investigators; Bolla, MK; Wang, Q; Jones, M; Schoemaker, M; Wesseling, J; van Leeuwen, FE; Van 't Veer, L; Easton, D; Swerdlow, AJ; Dowsett, M; Pharoah, PD; Schmidt, MK; Garcia-Closas, M (2016-10-18)
      Background The value of KI67 in breast cancer prognostication has been questioned due to concerns on the analytical validity of visual KI67 assessment and methodological limitations of published studies. Here, we investigate ...
    • Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. 

      Brouckaert, O; Rudolph, A; Laenen, A; Keeman, R; Bolla, MK; Wang, Q; Soubry, A; Wildiers, H; Andrulis, IL; Arndt, V; Beckmann, MW; Benitez, J; Blomqvist, C; Bojesen, SE; Brauch, H; Brennan, P; Brenner, H; Chenevix-Trench, G; Choi, J-Y; Cornelissen, S; Couch, FJ; Cox, A; Cross, SS; Czene, K; Eriksson, M; Fasching, PA; Figueroa, J; Flyger, H; Giles, GG; González-Neira, A; Guénel, P; Hall, P; Hollestelle, A; Hopper, JL; Ito, H; Jones, M; Kang, D; kConFab; Knight, JA; Kosma, V-M; Li, J; Lindblom, A; Lilyquist, J; Lophatananon, A; Mannermaa, A; Manoukian, S; Margolin, S; Matsuo, K; Muir, K; Nevanlinna, H; Peterlongo, P; Pylkäs, K; Saajrang, S; Seynaeve, C; Shen, C-Y; Shu, X-O; Southey, MC; Swerdlow, A; Teo, S-H; Tollenaar, RAEM; Truong, T; Tseng, C-C; van den Broek, AJ; van Deurzen, CHM; Winqvist, R; Wu, AH; Yip, CH; Yu, J-C; Zheng, W; Milne, RL; Pharoah, PDP; Easton, DF; Schmidt, MK; Garcia-Closas, M; Chang-Claude, J; Lambrechts, D; Neven, P (2017-11-07)
      Background Previous studies have shown that reproductive factors are differentially associated with breast cancer (BC) risk by subtypes. The aim of this study was to investigate associations between reproductive factors ...
    • Risk of Meningioma in European Patients Treated With Growth Hormone in Childhood: Results From the SAGhE Cohort. 

      Swerdlow, AJ; Cooke, R; Beckers, D; Butler, G; Carel, J-C; Cianfarani, S; Clayton, P; Coste, J; Deodati, A; Ecosse, E; Hokken-Koelega, ACS; Khan, AJ; Kiess, W; Kuehni, CE; Flück, CE; Pfaffle, R; Sävendahl, L; Sommer, G; Thomas, M; Tidblad, A; Tollerfield, S; Zandwijken, GRJ (2019-03)
      Context:There has been concern that GH treatment of children might increase meningioma risk. Results of published studies have been inconsistent and limited. Objective:To examine meningioma risks in relation to GH treatment. ...
    • Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers. 

      Smrke, A; Younger, E; Wilson, R; Husson, O; Farag, S; Merry, E; Macklin-Doherty, A; Cojocaru, E; Arthur, A; Benson, C; Miah, AB; Zaidi, S; Gennatas, S; Jones, RL (2020-07)
      <h4>Purpose</h4>Many patients with cancer, often those with rare cancers such as sarcomas, travel long distances to access expert care. The COVID-19 pandemic necessitated widespread changes in delivery of cancer care, ...
    • Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study. 

      Bodicoat, DH; Schoemaker, MJ; Jones, ME; McFadden, E; Griffin, J; Ashworth, A; Swerdlow, AJ (2014-02-04)
      Introduction Breast development and hormonal changes at puberty might affect breast cancer risk, but epidemiological analyses have focussed largely on age at menarche and not at other pubertal stages.Methods We investigated ...
    • Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience. 

      Kingston, B; Kayhanian, H; Brooks, C; Cox, N; Chaabouni, N; Redana, S; Kalaitzaki, E; Smith, I; O'Brien, M; Johnston, S; Parton, M; Noble, J; Stanway, S; Ring, A; Turner, N; Okines, A (2017-12)
      Purpose Leptomeningeal disease (LMD) is an uncommon complication of advanced breast cancer. The prognosis is poor, and although radiotherapy (RT), systemic and intra-thecal (IT) chemotherapy are accepted treatment modalities, ...